Logo do repositório
 
Publicação

Cytotoxic activity of fucoxanthin: a review of in vitro studies

2025-10-14Comunicação em conferência Acesso aberto
Ver registo simples
dc.contributor.authorRente, Ana
dc.contributor.authorCorreia, Patrícia
dc.contributor.authorPinho, Cláudia
dc.contributor.authorCorreia, Patrícia Carla dos Santos Correia
dc.contributor.authorPinho, Cláudia
dc.date.accessioned2026-04-21T09:09:33Z
dc.date.available2026-04-21T09:09:33Z
dc.date.issued2025-10-14
dc.description.abstractFucoxanthin, a marine carotenoid found in brown algae, has attracted attention for its unique structure, metabolism, safety and bioactivities [1]. Cancer is one of the leading causes of death worldwide and often treated with conventional drugs that have low survival rates and significant side effects [2–4]. Fucoxanthin has emerged as a promising natural anticancer agent, showing dose-dependent inhibitory effects on neuroblastoma, colon adenocarcinoma and lung carcinoma cell lines [3,5]; however, further research is required to fully explore its therapeutic potential. This review aims to discuss the cytotoxic activity, in vitro, of fucoxanthin against cancer cell lines. This narrative review was conducted using the PubMed database in order to find articles published between 2004 and 2024, related to the cytotoxic activity in vitro of fucoxanthin (natural or synthetic). Fucoxanthin showed significant cytotoxic effects on several cancer cell lines, including colon (HCT 116), melanoma (Malme-3M), cervical (SiHa), glioblastoma (GBM), leukaemia (HL-60) and endometrial adenocarcinoma (HEC-1-A) cells, with the effects being dose and time dependent [5–9]. Algae extracts outperformed pure fucoxanthin, suggesting synergistic effects with other compounds [5]. Additionally, fucoxanthin showed selective toxicity, targeting cancer cells while sparing normal cells, human umbilical vein endothelial cells (HUVEC) and human embryonic kidney cells (HEK-293) [5]. It also enhances the efficacy of chemotherapeutic drugs such as doxorubicin and cisplatin, particularly in triple-negative breast cancer, suggesting potential as an adjuvant therapy [10]. Fucoxanthin and its extracts exhibit selective cytotoxicity against cancer cells, often enhancing effectiveness when combined with other compounds or chemotherapy agents. The impact of these compound varies depending on concentration, exposure time, cell type, and whether it's used in pure or extract form. These findings suggest fucoxanthin's potential as an adjuvant for cancer treatment. However, further research is needed to clarify its mechanisms of action and assess its potential in vivo applications.eng
dc.identifier.citationRente, A., Correia , P., & Pinho, C. (2025). Cytotoxic activity of fucoxanthin: a review of in vitro studies. Proceedings of Research and Practice in Allied and Environmental Health, 2(4), 13. https://doi.org/10.26537/prpaeh.v2i4.6456
dc.identifier.doi10.26537/prpaeh.v2i4.6456
dc.identifier.issn2975-9420
dc.identifier.urihttp://hdl.handle.net/10400.22/32237
dc.language.isoeng
dc.peerreviewedyes
dc.publisherIPP
dc.relation.hasversionhttps://parc.ipp.pt/index.php/PRPAEH/article/view/6456
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCancer
dc.subjectCytotoxicity
dc.subjectFucoxanthin
dc.subjectin vitro
dc.titleCytotoxic activity of fucoxanthin: a review of in vitro studieseng
dc.typeconference paper
dspace.entity.typePublication
oaire.citation.conferenceDate2024-12-19
oaire.citation.conferencePlacePorto
oaire.citation.endPage6
oaire.citation.issue4
oaire.citation.startPage13
oaire.citation.titleProceedings of Research and Practice in Allied and Environmental Health - II Jornadas TSDT do Hospital de São João
oaire.citation.volume2
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameCorreia
person.familyNamePinho
person.givenNamePatrícia Carla dos Santos Correia
person.givenNameCláudia
person.identifier.ciencia-id221F-5A5F-BFC9
person.identifier.ciencia-id8B1B-A0D9-B6E4
person.identifier.orcid0000-0001-7869-7977
person.identifier.orcid0000-0002-3157-3712
relation.isAuthorOfPublication655ab14f-f60f-42c5-8c8a-19d5257ff5f6
relation.isAuthorOfPublication01c994b8-cb20-43a8-947c-d2b978283944
relation.isAuthorOfPublication.latestForDiscovery655ab14f-f60f-42c5-8c8a-19d5257ff5f6

Ficheiros

Coleções

ESS - CISA/LAQV Requimte - Comunicações em eventos científicos
ESS - FAR - Comunicações em eventos científicos